DGAP-News: CureVac / Key word(s): Quarter Results 
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates 
2021-05-26 / 13:00 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates 
- First-Generation COVID-19 vaccine program, CVnCoV 
- Phase 3 trial started with CVnCoV in adults suffering from selected comorbidities 
- Phase 2a trial in Peru and Panama assessing third booster vaccination at one and six month post second dose 
- CureVac participating in broad UK trial evaluating different COVID-19 vaccines as potential boosters at least three 
months following full primary vaccination 
- First preclinical data of second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates faster onset of antibody 
production and high variant cross-neutralization 
- Rolling submission with Swissmedic initiated after filing of first data package 
- Financials: cash position of EUR1.50 billion as of March 31, 2021 
 
TÜBINGEN, Germany/ BOSTON, USA - May 26, 2021 - CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company 
developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced 
business updates and financial results for the first quarter of 2021. 
"The COVID-19 reality has changed dramatically since the beginning of this year and is today characterized by the rapid 
spread of Variants of Concern as well as the emergence of new strains, which together have now all but supplanted the 
original virus strain that we fought throughout 2020," said Franz-Werner Haas, Chief Executive Officer of CureVac. "In 
this variant rich environment, we are convinced that our first-generation COVID-19 vaccine candidate, CVnCoV, will make 
an important contribution to the pandemic vaccination programs, for which availability of potent vaccines is now more 
important than ever to stop the virus from evolving further. CVnCoV is in the final stage of clinical development in 
what we believe is one of the most diverse efficacy trials in terms of the range of virus variants. For CVnCoV, which 
we advance together with our partner Bayer, we are expecting the data readout from the pivotal Phase 2b/3 trial in the 
second quarter, which will enable us to finalize our rolling submission with EMA. Our second-generation vaccine 
candidate, CV2CoV, is developed together with GSK and is planned to enter clinic trials in the third quarter of 2021. 
First preclinical data showed high potential for even lower doses that is expected to enable multivalent or combination 
vaccines to flexibly address different variants or different diseases in one vaccine." 
"In the first quarter of 2021, we were able to continue to build and strengthen our strong cash position with our first 
follow-on financing in February 2021, raising USD517.5 million in aggregated gross proceeds," said Pierre Kemula, Chief 
Financial Officer of CureVac. "Together with our strategic partners Bayer and GSK, we are fully dedicated to create 
sustainable value with our COVID-19 vaccine program - for the pandemic and beyond. This is further enabled by the 
ongoing ramp-up of our broad and integrated European manufacturing network as well as the RNA Printer, our autonomous 
and mobile manufacturing unit well suited to address pandemic preparedness. Build-up of our commercial infrastructure 
is progressing well as we prepare to potentially launch our first product and work toward our goal of becoming an 
integrated biopharma company." 
Selected Business Updates 
CVnCoV - First-Generation COVID-19 Vaccine Candidate 
CVnCoV is CureVac's first-generation vaccine candidate in its clinical COVID-19 vaccine program. Based on optimized, 
non-chemically modified mRNA, CVnCoV was shown to be well tolerated and induced robust immune responses at a 12µg dose 
in our Phase 1 clinical trial. Additionally, CVnCoV has shown to enable delivery logistics at standard refrigerator 
temperature - a critical advantage as the world faces a pandemic that demands safe vaccines produced and distributed on 
a global scale. 
Phase 3 in Belgium Including Participants with Comorbidities 
A Phase 3 trial to evaluate the safety, reactogenicity and immunogenicity of CVnCoV in adults with an elevated risk of 
severe COVID-19 disease due to comorbidities started in late April with vaccination of the first participant. The 
multicenter trial includes people with selected comorbidities such as obesity, chronic cardiovascular disease, chronic 
kidney disease, chronic obstructive pulmonary disease (COPD), HIV, type 2 diabetes mellitus and post-renal 
transplantation. It is currently being conducted in Belgium and is expected to enroll approximately 1,200 participants. 
Phase 2a in Peru and Panama 
To offer the best protection in the context of spreading virus variants, additional data is needed concerning the 
longevity of protection of current vaccines, as well as the need for and timing of potential booster vaccination. 
CureVac is currently assessing the benefit of a booster vaccination in its clinical Phase 2a trial in Peru and Panama. 
The Phase 2a trial, which serves as a dose-confirmation trial of a 12µg dose of CVnCoV for advanced clinical testing, 
is fully recruited at 674 participants and features approximately 270 participants in the important group above the age 
of 60, who received 12µg of CVnCoV. To assess the age-related need for a booster vaccination, the two-dose vaccination 
schedule was further extended by a third booster vaccination, administered to trial participants above the age of 60 
one month after the second dose and to all trial participants above the age of 18 six months after the second dose. No 
increase in reactogenicity was observed following administration of the booster vaccination compared to administration 
of the two doses of the primary vaccination. 
Inclusion of CVnCoV in UK COVID-19 Cov-Boost Vaccine Study 
On May 19, the UK Government announced the upcoming Cov-Boost trial, further extending current clinical research of 
booster vaccinations by investigating whether it is safe and effective to boost using a different vaccine from the one 
originally used for immunization. 
The study, which is the first of its kind, is scheduled to start at the beginning of June. It will be conducted at 18 
sites across the UK and is expected to include a total of 2,886 participants. Cov-Boost will evaluate several different 
COVID-19 vaccines as potential boosters, including CVnCoV, administered at least three months after participants have 
received their second initial vaccine dose. Each participant will receive one booster vaccine, which could be different 
from the one they have already received. Initial results of the study are expected in September 2021. 
 
Regulatory Pathway 
CureVac's recently founded Swiss subsidiary announced the initiation of a rolling submission process with the Swiss 
regulatory authority Swissmedic on April 19, 2021. Regulatory clearance of CVnCoV with Swissmedic will allow CureVac to 
serve the order of the Swiss federal government for the supply of five million vaccine doses, which forms part of the 
delivery agreement between the European Commission and CureVac. Next to Germany and Austria, Switzerland represents one 
of the three countries for which CureVac holds exclusive commercialization rights for Program Products in the context 
of its broad GSK partnership in vaccines for infectious diseases as well as second-generation vaccines for COVID-19. 
CV2CoV - Second-Generation COVID-19 Vaccine Candidate 
CV2CoV is CureVac's second-generation vaccine candidate in its COVID-19 vaccine program, developed in collaboration 
with GSK. Also based on non-chemically modified mRNA, CV2CoV features a new mRNA backbone optimized to improve 
intracellular mRNA translation for increased and extended protein expression. CV2CoV optimizations target strong immune 
responses at even lower doses compared to CVnCoV and could support the development of multivalent vaccines to target 
rapidly spreading COVID-19 variants. First clinical trials for CV2CoV are expected to start in the third quarter of 
2021. 
First Preclinical Study of CV2CoV on Immunogenicity and Variant Cross-Neutralization 
On May 13, CureVac published the first preclinical data of its second-generation COVID-19 vaccine candidate, CV2CoV, 
demonstrating high levels of antigen production in an in vitro setup as well as strong and dose-dependent immune 
responses in an established rat model. Preclinical data in animals immunized with two doses of CV2CoV in the dose range 
of 0.5-40µg demonstrated fast onset of strong immune responses already after the first dose. In addition, the serum of 
vaccinated animals showed significant cross-neutralization against variants first discovered in Denmark (B.1.1.298), 
the UK (B.1.1.7) and South Africa (B.1.351). The full manuscript is available on the pre-print server bioRxiv. 
Financial Update for the First Quarter of 2021 
Cash Position 
Cash and cash equivalents increased from EUR1,323 million as of December 31, 2020, to EUR1,497 million as of March 31, 
2021, mainly due to the raising of EUR405 million in net proceeds in a follow-on public offering, which closed in 
February 2021. In the first three months of 2021, cash used in operations was mainly used to advance all R&D activities 
for CVnCoV, our first-generation COVID-19 vaccine candidate. 
Revenues 
Revenue was EUR10.0 million for the first three months of 2021, representing an increase of EUR6.9 million or 221.6% 
compared to revenue of EUR3.1 million for the same period in 2020. 
This increase was primarily driven by EUR9.1 million in revenue recognized under our collaboration agreement with 
GlaxoSmithKline plc (GSK), entered into in July 2020, for the research, development, manufacturing and

(MORE TO FOLLOW) Dow Jones Newswires

May 26, 2021 07:01 ET (11:01 GMT)